76 related articles for article (PubMed ID: 22608846)
21. A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.
Le Gouëllec A; Chauchet X; Laurin D; Aspord C; Verove J; Wang Y; Genestet C; Trocme C; Ahmadi M; Martin S; Broisat A; Cretin F; Ghezzi C; Polack B; Plumas J; Toussaint B
Mol Ther; 2013 May; 21(5):1076-86. PubMed ID: 23531551
[TBL] [Abstract][Full Text] [Related]
22. Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.
Kochhar S
Hum Vaccin Immunother; 2013 Apr; 9(4):928-31. PubMed ID: 23322007
[TBL] [Abstract][Full Text] [Related]
23. Bacterial vectors for active immunotherapy reach clinical and industrial stages.
Le Gouëllec A; Chauchet X; Polack B; Buffat L; Toussaint B
Hum Vaccin Immunother; 2012 Oct; 8(10):1454-8. PubMed ID: 22894945
[TBL] [Abstract][Full Text] [Related]
24. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.
Brockstedt DG; Bahjat KS; Giedlin MA; Liu W; Leong M; Luckett W; Gao Y; Schnupf P; Kapadia D; Castro G; Lim JY; Sampson-Johannes A; Herskovits AA; Stassinopoulos A; Bouwer HG; Hearst JE; Portnoy DA; Cook DN; Dubensky TW
Nat Med; 2005 Aug; 11(8):853-60. PubMed ID: 16041382
[TBL] [Abstract][Full Text] [Related]
25. Generation of killed but metabolically active (KBMA) Edwardsiella tarda and evaluation of its potential as a protective vaccine.
Choi SH; Kim MS; Kim KH
Fish Shellfish Immunol; 2015 Aug; 45(2):889-94. PubMed ID: 26074095
[TBL] [Abstract][Full Text] [Related]
26. Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections.
Meynet E; Laurin D; Lenormand JL; Camara B; Toussaint B; Le Gouëllec A
Vaccine; 2018 Mar; 36(14):1893-1900. PubMed ID: 29506924
[TBL] [Abstract][Full Text] [Related]
27. Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector.
Lankowski AJ; Hohmann EL
J Infect Dis; 2007 Apr; 195(8):1203-11. PubMed ID: 17357059
[TBL] [Abstract][Full Text] [Related]
28. Killed but metabolically active vaccines.
Dubensky TW; Skoble J; Lauer P; Brockstedt DG
Curr Opin Biotechnol; 2012 Dec; 23(6):917-23. PubMed ID: 22608846
[TBL] [Abstract][Full Text] [Related]
29. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic.
Singh R; Wallecha A
Hum Vaccin; 2011 May; 7(5):497-505. PubMed ID: 21422819
[TBL] [Abstract][Full Text] [Related]
30. Live-attenuated Listeria-based immunotherapy.
Rothman J; Paterson Y
Expert Rev Vaccines; 2013 May; 12(5):493-504. PubMed ID: 23659298
[TBL] [Abstract][Full Text] [Related]
31. Vaccines against leishmaniasis.
Modabber F
Ann Trop Med Parasitol; 1995 Dec; 89 Suppl 1():83-8. PubMed ID: 8745930
[TBL] [Abstract][Full Text] [Related]
32. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.
Brockstedt DG; Dubensky TW
Expert Rev Vaccines; 2008 Sep; 7(7):1069-84. PubMed ID: 18767955
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
